| P50 | author | Ulf Landmesser | Q27235435 |
| P2093 | author name string | Helmut Drexler | |
| P2860 | cites work | Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group | Q28144874 |
| | Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial | Q28203758 |
| | Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial | Q28258946 |
| | Combination of isosorbide dinitrate and hydralazine in blacks with heart failure | Q28292266 |
| | The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 |
| | beta-adrenergic receptor blockade in chronic heart failure | Q33831388 |
| | Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure | Q34101478 |
| | Reversal of Chronic Molecular and Cellular Abnormalities Due to Heart Failure by Passive Mechanical Ventricular Containment | Q47438363 |
| | Bone marrow stem cells for myocardial infarction: effector or mediator? | Q50781532 |
| | Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure. | Q51663682 |
| | Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. | Q53399782 |
| | Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. | Q53612767 |
| | Erythropoietin regulates endothelial progenitor cells | Q53854344 |
| | Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes | Q57484579 |
| | Myoblast transplantation for heart failure | Q58109127 |
| | Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD) | Q68430599 |
| | Association of serum digoxin concentration and outcomes in patients with heart failure | Q73004928 |
| | The effect of digoxin on mortality and morbidity in patients with heart failure | Q73080377 |
| | Beta-blockers in chronic heart failure | Q73199458 |
| | A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure | Q73956766 |
| | Sex-based differences in the effect of digoxin for the treatment of heart failure | Q78455630 |
| | A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure | Q34106793 |
| | Long-term use of a left ventricular assist device for end-stage heart failure. | Q34109624 |
| | Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban | Q34180320 |
| | Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial | Q34246891 |
| | Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Q34246898 |
| | Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure | Q34321811 |
| | Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). | Q34383304 |
| | Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure | Q34386004 |
| | The effect of cardiac resynchronization on morbidity and mortality in heart failure | Q34400885 |
| | Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling | Q34960679 |
| | A mechanistic role for cardiac myocyte apoptosis in heart failure | Q34997938 |
| | Targeting calcium cycling proteins in heart failure through gene transfer | Q35037546 |
| | Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic | Q35040738 |
| | Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention | Q35077389 |
| | A novel protective effect of erythropoietin in the infarcted heart | Q36001255 |
| | Clinical applications of stem cells for the heart | Q36030311 |
| | Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy | Q37149829 |
| | Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both | Q39669015 |
| | Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. | Q40470495 |
| | The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study | Q43636269 |
| | Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction | Q43721244 |
| | Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy | Q43797629 |
| | Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies | Q44015014 |
| | Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. | Q44074134 |
| | Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). | Q44079566 |
| | Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure | Q44221550 |
| | Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase | Q44243299 |
| | Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial | Q44270436 |
| | Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). | Q44366517 |
| | Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study | Q44485270 |
| | Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Q44588075 |
| | The relationship between cholesterol and survival in patients with chronic heart failure | Q44684614 |
| | Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? | Q44684620 |
| | Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? | Q45091736 |
| | Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase | Q45091743 |
| | Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy | Q45119477 |
| | Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III - IV congestive heart failure | Q45120611 |
| | Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. | Q45244379 |
| | Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery | Q45888008 |
| | Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction | Q46455349 |
| | Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans | Q46468933 |
| | Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). | Q46478452 |
| P433 | issue | 12 | |
| P921 | main subject | heart failure | Q181754 |
| | chronic heart failure | Q11829287 |
| P304 | page(s) | 628-638 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | Nature Clinical Practice Cardiovascular Medicine | Q15727036 |
| P1476 | title | Chronic heart failure: an overview of conventional treatment versus novel approaches | |
| P478 | volume | 2 | |